Análisis

Domestic and foreign pharma firms showcased new combination drugs targeting dyslipidemia alongside hypertension and diabetes at the 15th Korean Society of Lipid and Atherosclerosis International Congress.

Celltrion's omalizumab biosimilar OmliClon expands to 26 European countries, achieving over 90% market share in Spain and exceeding sales targets in Italy.

Sandoz aims to grow its biosimilar lineup from 13 to over 100 products by 2040, boosting post‑patent‑cliff revenue share to 80% and targeting a double in net sales by the mid‑2030s.

US consumers are increasingly seeking clean‑ingredient women’s health products; Good Clean Love’s Almost Naked lubricant tops sales.

Young patients with ankylosing spondylitis are seeing a shift from injectable biologics to Pfizer’s oral JAK inhibitor, tofacitinib, now covered as first‑line treatment.

BaroPharm filed a securities report with the Financial Services Commission and announced a public offering of 1.78 million shares, targeting a 16,400‑22,200 KRW price range, aiming for a KOSDAQ listing this year.

Hanmi Science will replace the cans of its pharmacy‑only health drink ‘Premium Recipe’ line with 120 mL bottles, rolling out the new packaging to Korean pharmacies from September.

Korea Pfizer and Il Dong Pharmaceutical have signed a distribution and joint promotion agreement for the migraine drug Nutex oral disintegrating tablet, leveraging Il Dong's CNS sales expertise to accelerate market entry.

GeoYoung Group’s GPO subsidiary CareCamp reported first‑half sales of 7.292 trillion KRW, a 15.9% YoY increase, and operating profit of 1.28 trillion KRW, up 29.1%.

Carvykti, approved in 2022, posted $657 M Q2 net sales, up 50% YoY, but expanding its patient‑specific manufacturing remains a key hurdle.

Effective control of drug stock, including expiry dates and storage conditions, impacts pharmacy revenue, cash flow, and tax burden.

Analysis of 25,862 operating pharmacies shows a move from friendly names like 'Health' to business‑focused names such as '365' and 'Mega'.